In the past week, TERN stock has gone up by 4.10%, with a monthly gain of 34.44% and a quarterly surge of 22.29%. The volatility ratio for the week is 5.65%, and the volatility levels for the last 30 days are 3.78% for Terns Pharmaceuticals Inc The simple moving average for the last 20 days is 10.00% for TERN’s stock, with a simple moving average of -20.50% for the last 200 days.
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
Moreover, the 36-month beta value for TERN is -0.15. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TERN is 66.42M and currently, short sellers hold a 8.19% of that float. On June 26, 2025, TERN’s average trading volume was 1.00M shares.
TERN) stock’s latest price update
Terns Pharmaceuticals Inc (NASDAQ: TERN) has experienced a rise in its stock price by 7.12 compared to its previous closing price of 3.79. However, the company has seen a gain of 4.10% in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024
Analysts’ Opinion of TERN
Oppenheimer, on the other hand, stated in their research note that they expect to see TERN reach a price target of $82. The rating they have provided for TERN stocks is “Outperform” according to the report published on October 31st, 2024.
Mizuho gave a rating of “Buy” to TERN, setting the target price at $16 in the report published on June 22nd of the previous year.
TERN Trading at 25.35% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.39% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Burroughs Amy L., who purchase 23,314 shares at the price of $3.87 back on Jun 25 ’25. After this action, Burroughs Amy L. now owns 47,083 shares of Terns Pharmaceuticals Inc, valued at $90,230 using the latest closing price.
Gengos Andrew, the Chief Financial Officer of Terns Pharmaceuticals Inc, purchase 10,000 shares at $3.73 during a trade that took place back on Jun 13 ’25, which means that Gengos Andrew is holding 10,000 shares at $37,350 based on the most recent closing price.
Stock Fundamentals for TERN
The total capital return value is set at -0.32. Equity return is now at value -32.12, with -30.84 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -58.02.
Currently, EBITDA for the company is -87.7 million with net debt to EBITDA at 1.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.89.
Conclusion
To wrap up, the performance of Terns Pharmaceuticals Inc (TERN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
